A Phase I/II Study of a Novel Reduced Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation in Patients With Multiple Myeloma

Trial Profile

A Phase I/II Study of a Novel Reduced Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation in Patients With Multiple Myeloma

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 24 Feb 2016

At a glance

  • Drugs Bortezomib (Primary) ; Antithymocyte globulin; Melphalan; Sirolimus; Tacrolimus; Tacrolimus
  • Indications Graft-versus-host disease; Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Feb 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 19 Jan 2011 Additional lead investigator identified as reported by ClinicalTrials.gov.
    • 12 Oct 2010 Planned initiation date changed from 1 Oct 2009 to 1 Jan 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top